NPR
FDA panel considers easing peptide restrictions
+968 words added -519 words removed
Accessibility links Skip to main content Keyboard shortcuts for audio player Open Navigation Menu --> Newsletters NPR Shop Get NPR+ Close Navigation Menu Home News Expand/collapse submenu for News National World Politics Business Health Science Climate Race Culture Expand/collapse submenu for Culture Books Movies Television Pop Culture Food Art & Design Performing Arts Life Kit Gaming Music Expand/collapse submenu for Music Tiny Desk New Music Friday All Songs Considered Music Features Live Sessions Podcasts & Shows Expand/collapse submenu for Podcasts & Shows Daily Morning Edition Weekend Edition Saturday Weekend Edition Sunday All Things Considered Up First Here & Now NPR Politics Podcast Featured Wait Wait...Don't Tell Me! Sarah Silbiger/Getty Images hide caption
For the latest stories on the science of healthy living, subscribe to NPR's Health newsletter.
Health RFK Jr.
Short Wave Does the science of peptides live up to the hype?
Peptides are strings of amino acids — smaller than a protein — that often act as signaling molecules in our bodies and carry out many critical functions.
They can be synthesized and delivered as drugs, often by injection. Some of those, like insulin, are naturally occurring in the body. Others are modified versions, as with the blockbuster GLP-1 obesity drugs.
Sponsor Message
Become an NPR sponsor
− Fresh Air Wild Card with Rachel Martin It's Been a Minute Embedded Get NPR+ More Podcasts & Shows Search Newsletters NPR Shop Get NPR+ Tiny Desk New Music Friday All Songs Considered Music Features Live Sessions About NPR Diversity Support Careers Press Ethics Advisers to the FDA will vote on easing regulation of 7 popular peptides Advisers to the Food and Drug Administration are weighing the evidence for seven different peptides.
+ Fresh Air Wild Card with Rachel Martin It's Been a Minute Embedded Get NPR+ More Podcasts & Shows Search Newsletters NPR Shop Get NPR+ Tiny Desk New Music Friday All Songs Considered Music Features Live Sessions About NPR Diversity Support Careers Press Ethics Advisers to the FDA will vote to ease regulation of popular peptides Advisers to the Food and Drug Administration voted in favor of easing regulation of popular peptides.
− Favorable votes would pave the way for easier access.
+ The recommendations could pave the way for specialized pharmacies to produce them in the U.S.
− Health FDA panel considers easing peptide restrictions July 23, 20265:00 AM ET By
Will Stone
A panel of advisers to the Food and Drug Administration will vote on recommendations for seven popular peptides.
+ Health FDA panel backs easier access to peptides Updated July 23, 20263:35 PM ET Originally published July 23, 20265:00 AM ET Heard on All Things Considered By
Will Stone
A panel of advisers to the Food and Drug Administration is making recommendations on seven popular peptides.
− A slate of experimental peptide therapies are under scrutiny today in what marks the beginning of a two-day meeting to help determine whether the compounds will become available from specialized pharmacies.
+ A panel of advisers to the Food and Drug Administration is recommending that the federal government green-light the production of two popular peptides by specialized pharmacies in the U.S.
+ The actions came during a highly anticipated two-day meeting that began Thursday to consider whether current Biden-era restrictions on production of seven different peptides — none of which are approved drugs — should be lifted.
− defends his health agenda and Trump's proposed budget cuts in hearing The panel of advisers to the Food and Drug Administration is considering the evidence for seven compounds including some of the most sought-after: TB-500, BPC-157 and MOTS-c.
+ defends his health agenda and Trump's proposed budget cuts in hearing An analysis presented by FDA scientists didn't support easing restrictions on BPC-157, often used for ulcerative colitis, or KPV, a peptide used for inflammation.
− None of them has undergone the kind of large-scale trials to establish safety and effectiveness that are required for FDA drug approvals.
+ Despite that analysis, the panel voted identically for each: 8-6 in favor and one abstention. (There were two separate votes on each peptide because there are two chemical variants under review for each one.)
The committee's backing represents a win for the peptide industry and consumers who support use of peptides. It also signals potential support for the other peptides on the agenda.
− And yet the therapies have attracted enormous attention in the wellness space.
+ The recommendations could pave the way for the FDA to reclassify the compounds so they can be obtained from specialized pharmacies in the U.S.
− They're promoted for injury recovery, muscle growth and fat loss, skin health, enhancing metabolism and more.
+ The FDA isn't bound by the committee's recommendations but typically follows them.
− Proponents argue that the current Biden-era restrictions on compounding of the substances — due to safety concerns and a lack of data — have fueled a risky gray market of overseas suppliers.
− The meeting represents yet another tension point between Health Secretary Robert F. Kennedy Jr.'s Make America Healthy Again agenda and the traditional medical and scientific establishment.
+ Health Secretary Robert F Kennedy Jr., who ultimately oversees the FDA, has publicly endorsed easing restrictions on peptides.
− Kennedy has publicly advocated for lifting restrictions on peptides and talked up their benefits.
+ The advisory panel was recently overhauled, and many of the new members have ties to the peptide industry, leading to criticism about potential conflicts of interest.
− Meanwhile, FDA scientists are recommending against giving compounding pharmacies the go-ahead to produce any of the seven peptides under consideration. In a review of the evidence, they repeatedly note the data comes primarily from preclinical work involving animals — and is quite limited for humans.
+ Additional voting members were added this week.
− For example, BPC-157 is based on a peptide found in human stomach juices, while TB-500 is related to a molecule found in many types of cells, called thymosin beta-4.
+ As with all the compounds under consideration, BPC-157 and KPV haven't undergone the same kind of large-scale trials as those peptide medications to establish safety and effectiveness, which is required for FDA drug approvals.
− In June, the FDA overhauled the roster for the advisory committee.
+ And yet the therapies have attracted enormous attention in the wellness space.
− Many of the new members have ties to the peptide industry.
+ They're typically promoted together and often taken in combination for injury recovery, muscle growth and fat loss, improving athletic performance, enhancing metabolism and more.
The discussion around BPC-157 was a study in contrasts — and signals the favorable direction the committee could likely take for all the compounds at issue.
For nearly two hours of public comment, the panel heard mostly from clinicians whose companies offer peptides and representatives of the compounding pharmacy industry.
− Earlier this week, the agency made further changes, adding a handful of temporary voting members, largely from academic institutions.
+ Many described the perils of the gray market for these substances, which are sold online with disclaimers, such as "for research use only" and "not for human consumption."
"Many of my patients are already using these drugs. They're just getting them from the worst possible places," Dr. Jessica Duncan, chief medical officer of the telehealth company IVIM Health, told the panel.
− The FDA committee is tasked with reviewing data that supports using these peptides for specific conditions, including migraines, ulcerative colitis, opioid withdrawal and wound healing.
+ "The question in front of you isn't whether people will use these.
− However, if the FDA ultimately reclassifies them, clinicians would have discretion to write prescriptions outside of those narrow indications.
+ They already are," she said. "It's whether they use them with a doctor and a licensed pharmacy or completely alone."
Meanwhile, the FDA's own scientists made the case for keeping the restrictions in place and spoke extensively about the lack of available data on safety and efficacy.
− The agenda for Thursday includes votes on four compounds: BPC-157, KPV, TB-500 and MOTs-C.
+ Most of the evidence on BPC-157 — which is based on a peptide found in human stomach juices —comes from preclinical work involving animals, and is quite limited for humans.
Beyond that, FDA official Russell Wesdyk said a "foundational challenge" with BPC-157 and all the substances under consideration is that the agency can't actually define what they are.
− On Friday, the panel will review three other peptides: Emideltide, Epitalon and Semax.
+ There is variation in chemical composition for peptides labeled with the same name, he explained.
− The committee will discuss each peptide one by one and vote on recommendations throughout the day, though FDA leadership makes the final call on whether to green-light the products.
+ "You will see many many different forms," he said, "We can't create quality standards until we actually know what it is."
The FDA committee was tasked with reviewing data that supports using these peptides to treat specific conditions — in the case of BPC-157 for treating the inflammatory bowel disease, ulcerative colitis.
+ However, if the FDA ultimately reclassifies them and they are produced by compounding pharmacies in the U.S., clinicians would have discretion to write prescriptions outside of those narrow indications.
During the meeting, industry groups said the agency's review did not reflect more recent scientific data BPC-157, including results from other human studies that had been submitted ahead of time. Staff said it would take those into account before making a final decision.
Some committee members directly echoed the sentiments of those in the industry who spoke at the meeting, including Dr. Kris Wusterhausen, founder of a Texas-based medical practice that advertises hormone optimization and peptide therapies.
"Once you see the effects of BPC, you can't unsee it," he said while explaining his yes vote.
But others worried that placing the products on the FDA's official list for compounding will send the wrong message to the public, which may not be aware of the limited data for humans.
"I think this endorsement can be potentially harmful and I cannot in good conscience vote yes," said Dr. Brian Lee, a member of the panel and an associate professor at the Keck School of Medicine of USC.
The agenda for Thursday afternoon includes votes on three other compounds: KPV, TB-500 and MOTs-C. On Friday, the panel will review three other peptides: Emideltide, Epitalon and Semax.